The Michael J. Fox Foundation for Parkinson's Research awarded Civitas Therapeutics a $1 million grant to support a Phase II study of CVT-301, its lead drug candidate for intermittent debilitating motor fluctuations, which affect many patients with Parkinson's disease. The drug is an inhaled formulation of levodopa, whose approved indications include OFF episodes.

Related Summaries